With 1 million new cases and 200,000 children dead each year, Tuberculosis (TB) is now the leading cause of death from infectious diseases for children of all ages globally (UNICEF). ImproViTB is among the first pediatric clinical studies in the Central African region aimed at improving the clinical outcome and quality of life of children with pulmonary tuberculosis through a standard antituberculosis treatment supplemented with vitamin D.
This project is lead by a consortium of research institutions and universities from 4 Central African countries (Republic of Congo, Democratic Republic of Congo, Cameroon and Gabon) and 3 European countries, coordinated by CANTAM (Prof. Francine Ntoumi), the Network of Excellence in clinical research for Central African region.

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

Liberia

With comments as “the project is likely to have a significant impact”, and “this project will make a substantial contribution to the expected impact”, the reviewers of the European Union

Controlled Human Infection Model (CHIM) studies

In a Controlled Human Infection Model (CHIM) study, a well-characterised strain of an infectious agent is given to carefully selected adult volunteers in order to better understand human diseases, how they spread, and

AfriEthique

A European-African partnership aimed at improving the ethics and regulatory capacity of clinical research in Central African countries has successfully proposed its project (AfriHetique) to the European Commission (EDCTP). The partnership